These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6328136)

  • 1. PGE1 and prostacyclin suppression of NK-cell mediated cytotoxicity and its relation to cyclic AMP.
    Lanefelt F; Ullberg M; Jondal M; Fredholm BB
    Med Biol; 1983; 61(6):324-30. PubMed ID: 6328136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity.
    Goto T; Herberman RB; Maluish A; Strong DM
    J Immunol; 1983 Mar; 130(3):1350-5. PubMed ID: 6185577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human NK cell cytotoxicity by induction of cyclic AMP depends on impaired target cell recognition.
    Ullberg M; Jondal M; Lanefelt F; Fredholm BB
    Scand J Immunol; 1983 Apr; 17(4):365-73. PubMed ID: 6188204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
    Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
    J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding.
    Ramstedt U; Ng J; Wigzell H; Serhan CN; Samuelsson B
    J Immunol; 1985 Nov; 135(5):3434-8. PubMed ID: 2995494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
    Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.
    Underwood DC; Osborn RR; Novak LB; Matthews JK; Newsholme SJ; Undem BJ; Hand JM; Torphy TJ
    J Pharmacol Exp Ther; 1993 Jul; 266(1):306-13. PubMed ID: 8392555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle.
    Challiss RA; Adams D; Mistry R; Nicholson CD
    Br J Pharmacol; 1998 May; 124(1):47-54. PubMed ID: 9630342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of human natural cytotoxicity by IgG. II. Cyclic AMP as a mediator of monomeric IgG-induced inhibition of natural killer cell activity.
    Bancu AC; Gherman M; Sulica A; Goto T; Farrar W; Herberman RB
    Cell Immunol; 1988 Jul; 114(2):246-56. PubMed ID: 2455604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of human natural killing. III. Mechanism for interferon induction of loss of susceptibility to suppression by cyclic AMP elevating agents.
    Leung KH; Koren HS
    J Immunol; 1984 Mar; 132(3):1445-50. PubMed ID: 6319493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
    Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D
    J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin.
    Hopkins NK; Gorman RR
    J Clin Invest; 1981 Feb; 67(2):540-6. PubMed ID: 6257764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of natural killer cell activity by therapeutic levels of theophylline.
    Coskey LA; Bitting J; Roth MD
    Am J Respir Cell Mol Biol; 1993 Dec; 9(6):659-65. PubMed ID: 8257597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of human natural killer cell activity by pharmacological mediators.
    Hall TJ; Chen SH; Brostoff J; Lydyard PM
    Clin Exp Immunol; 1983 Nov; 54(2):493-500. PubMed ID: 6317242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.